Cargando…

Colistin versus polymyxin B: A pragmatic assessment of renal and neurological adverse effects and effectiveness in multidrug-resistant Gram-negative bacterial infections

OBJECTIVES: Our study aimed to evaluate the real-world data on renal and neurological adverse effects and effectiveness of colistimethate sodium (CMS) and polymyxin B (PMB). MATERIALS AND METHODS: An observational prospective study was performed on inpatients receiving CMS and PMB for multidrug-resi...

Descripción completa

Detalles Bibliográficos
Autores principales: Simon, Veneta, Viswam, Aathira, Alexander, Pallavi Sarah, James, Emmanuel, Sudhindran, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10657617/
https://www.ncbi.nlm.nih.gov/pubmed/37737075
http://dx.doi.org/10.4103/ijp.ijp_762_20
_version_ 1785137258071851008
author Simon, Veneta
Viswam, Aathira
Alexander, Pallavi Sarah
James, Emmanuel
Sudhindran, S.
author_facet Simon, Veneta
Viswam, Aathira
Alexander, Pallavi Sarah
James, Emmanuel
Sudhindran, S.
author_sort Simon, Veneta
collection PubMed
description OBJECTIVES: Our study aimed to evaluate the real-world data on renal and neurological adverse effects and effectiveness of colistimethate sodium (CMS) and polymyxin B (PMB). MATERIALS AND METHODS: An observational prospective study was performed on inpatients receiving CMS and PMB for multidrug-resistant Gram-negative bacterial infections. CMS dose was titrated to renal function, and serum creatinine was assessed daily. The incidence of nephrotoxicity, the primary outcome, was evaluated based on an increase in serum creatinine from baseline as well as by the Risk, Injury, Failure, Loss of kidney function, and End-stage renal disease criteria. Neurological adverse effects were assessed based on clinical signs and symptoms, and the causality and severity were assessed by the Naranjo scale and modified Hartwig–Siegel scale, respectively. The effectiveness of polymyxin therapy was ascertained by a composite of microbiological eradication of causative bacteria and achievement of clinical cure. Thirty-day all-cause mortality was also determined. RESULTS: Between CMS and PMB, the incidence of nephrotoxicity (59.3% vs. 55.6%, P = 0.653) or neurotoxicity (8.3% vs. 5.6%, P = 0.525) did not significantly differ. However, reversal of nephrotoxicity was significantly more with patients receiving CMS than PMB (48.4% vs. 23.3%, P = 0.021). Favorable clinical outcomes (67.6% vs. 37%, P < 0.001) and microbiological eradication of causative bacteria (73.1% vs. 46.3%, P = 0.001) were significantly more with CMS than PMB. Patients treated with CMS had lower all-cause mortality than those with PMB treatment (19.4% vs. 42.6%, P = 0.002). CONCLUSION: There is no significant difference in the incidence of renal and neurotoxic adverse effects between CMS and PMB when CMS is administered following renal dose modification. CMS shows better effectiveness and lower mortality compared to PMB.
format Online
Article
Text
id pubmed-10657617
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-106576172023-07-01 Colistin versus polymyxin B: A pragmatic assessment of renal and neurological adverse effects and effectiveness in multidrug-resistant Gram-negative bacterial infections Simon, Veneta Viswam, Aathira Alexander, Pallavi Sarah James, Emmanuel Sudhindran, S. Indian J Pharmacol Research Article OBJECTIVES: Our study aimed to evaluate the real-world data on renal and neurological adverse effects and effectiveness of colistimethate sodium (CMS) and polymyxin B (PMB). MATERIALS AND METHODS: An observational prospective study was performed on inpatients receiving CMS and PMB for multidrug-resistant Gram-negative bacterial infections. CMS dose was titrated to renal function, and serum creatinine was assessed daily. The incidence of nephrotoxicity, the primary outcome, was evaluated based on an increase in serum creatinine from baseline as well as by the Risk, Injury, Failure, Loss of kidney function, and End-stage renal disease criteria. Neurological adverse effects were assessed based on clinical signs and symptoms, and the causality and severity were assessed by the Naranjo scale and modified Hartwig–Siegel scale, respectively. The effectiveness of polymyxin therapy was ascertained by a composite of microbiological eradication of causative bacteria and achievement of clinical cure. Thirty-day all-cause mortality was also determined. RESULTS: Between CMS and PMB, the incidence of nephrotoxicity (59.3% vs. 55.6%, P = 0.653) or neurotoxicity (8.3% vs. 5.6%, P = 0.525) did not significantly differ. However, reversal of nephrotoxicity was significantly more with patients receiving CMS than PMB (48.4% vs. 23.3%, P = 0.021). Favorable clinical outcomes (67.6% vs. 37%, P < 0.001) and microbiological eradication of causative bacteria (73.1% vs. 46.3%, P = 0.001) were significantly more with CMS than PMB. Patients treated with CMS had lower all-cause mortality than those with PMB treatment (19.4% vs. 42.6%, P = 0.002). CONCLUSION: There is no significant difference in the incidence of renal and neurotoxic adverse effects between CMS and PMB when CMS is administered following renal dose modification. CMS shows better effectiveness and lower mortality compared to PMB. Wolters Kluwer - Medknow 2023 2023-09-11 /pmc/articles/PMC10657617/ /pubmed/37737075 http://dx.doi.org/10.4103/ijp.ijp_762_20 Text en Copyright: © 2023 Indian Journal of Pharmacology https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Research Article
Simon, Veneta
Viswam, Aathira
Alexander, Pallavi Sarah
James, Emmanuel
Sudhindran, S.
Colistin versus polymyxin B: A pragmatic assessment of renal and neurological adverse effects and effectiveness in multidrug-resistant Gram-negative bacterial infections
title Colistin versus polymyxin B: A pragmatic assessment of renal and neurological adverse effects and effectiveness in multidrug-resistant Gram-negative bacterial infections
title_full Colistin versus polymyxin B: A pragmatic assessment of renal and neurological adverse effects and effectiveness in multidrug-resistant Gram-negative bacterial infections
title_fullStr Colistin versus polymyxin B: A pragmatic assessment of renal and neurological adverse effects and effectiveness in multidrug-resistant Gram-negative bacterial infections
title_full_unstemmed Colistin versus polymyxin B: A pragmatic assessment of renal and neurological adverse effects and effectiveness in multidrug-resistant Gram-negative bacterial infections
title_short Colistin versus polymyxin B: A pragmatic assessment of renal and neurological adverse effects and effectiveness in multidrug-resistant Gram-negative bacterial infections
title_sort colistin versus polymyxin b: a pragmatic assessment of renal and neurological adverse effects and effectiveness in multidrug-resistant gram-negative bacterial infections
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10657617/
https://www.ncbi.nlm.nih.gov/pubmed/37737075
http://dx.doi.org/10.4103/ijp.ijp_762_20
work_keys_str_mv AT simonveneta colistinversuspolymyxinbapragmaticassessmentofrenalandneurologicaladverseeffectsandeffectivenessinmultidrugresistantgramnegativebacterialinfections
AT viswamaathira colistinversuspolymyxinbapragmaticassessmentofrenalandneurologicaladverseeffectsandeffectivenessinmultidrugresistantgramnegativebacterialinfections
AT alexanderpallavisarah colistinversuspolymyxinbapragmaticassessmentofrenalandneurologicaladverseeffectsandeffectivenessinmultidrugresistantgramnegativebacterialinfections
AT jamesemmanuel colistinversuspolymyxinbapragmaticassessmentofrenalandneurologicaladverseeffectsandeffectivenessinmultidrugresistantgramnegativebacterialinfections
AT sudhindrans colistinversuspolymyxinbapragmaticassessmentofrenalandneurologicaladverseeffectsandeffectivenessinmultidrugresistantgramnegativebacterialinfections